Vaccine Info

Cervavac HPV Vaccine

Authored by
Last reviewed
September 3, 2022
Fact checked by
Robert Carlson, MD

Cervavac HPV Vaccine Description 2022

Serum Institute of India (SII) 's Cervavac is the first quadrivalent human papillomavirus vaccine made in India, protecting against HPV types 6, 11, 16, and 18. Cervavac was studied in vaccine trials that were started in September 2018 in 12 sites across India.  

Cervavac was launched on September 1, 2022, after the Drugs Controller General of India (DCGI) had granted market authorization to the Pune-based Serum Institute of India (SII) to manufacture the vaccine.

In the application to the DCGI, Singh stated that the qHPV vaccine Cervavac has demonstrated a robust antibody response nearly 1,000 times higher than the baseline against all targeted HPV types and in all doses and age groups.

Pune-based Serum Institute of India is now the world's largest vaccine manufacturer by the number of doses produced and sold globally (more than 1.5 billion doses), which includes Polio vaccine, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, Rubella as well as Pneumococcal and Covid-19 vaccines. 

Additional HPV vaccine information is posted at

Cervavac Price

Adar Poonawalla, CEO of SSI, stated: The Cervavac vaccine price range would be Rs 200-400.

Cervavac Availability

SSI indicated Cervavac vaccine would be available in 2022 through the government channel in India.

Cervavac Vaccine Indication

Cervical cancer is by far the most common HPV-related disease. A majority of this type of cancer – more than 95% – is caused because of HPV. In India, cervical cancer is the second-most common cancer, especially among women between 15 and 44 years of age. Every year 122,844 Indian women are diagnosed with cervical cancer, and 67,477 die from the disease, according to figures from 2012, says NHP.

Cervavac Vaccine News 2022

September 1, 2022 - News article: Serum Institute's qHPV vaccine is a game changer.

September 1, 2022 - Announcing the scientific completion of the quadrivalent Human Papilloma Virus (qHPV) vaccine in presence of Mr. Adar C. Poonawalla, CEO, Serum Institute of India, Pune, and other prominent scientists and dignitaries, Dr. Jitendra Singh said, this affordable and cost-effective vaccine marks an important day for DBT and BIRAC as it takes India a step closer to PM Modi's vision of Atmanirbhar Bharat.

July 18, 2022 - The Serum Institute of India received regulatory approval to sell an indigenously developed HPV vaccine that can prevent cervical cancer. The Drugs Controller General of India granted market authorization for the Quadrivalent Human Papillomavirus vaccine (qHPV). 

June 15, 2022 - ANI reported the Drugs Controller General of India's Subject Expert Committee recommended granting market authorization to the Serum Institute of India to manufacture India's indigenously-developed CERVAVAC Quadrivalent Human Papillomavirus vaccine (qHPV).

Cervavac Vaccine Clinical Trials

Serum Institute of India applied for market authorization after completing the phase 2/3 clinical trial with the support of the Department of Biotechnology to ensure its early availability in the country," said the sources.

Clinical Trials

No clinical trials found